Poly Medicure Limited , a prominent player in the medical devices industry, has announced a final dividend of ₹3.50 per equity share for the financial year 2024-25. The company has set September 18, 2025, as the record date for determining shareholders eligible for the dividend payout.

Key Details of the Dividend Announcement

Shareholder Approval and AGM

The final dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) scheduled for September 25, 2025. The company's share transfer books will remain closed during the book closure period to facilitate the dividend distribution process.

Regulatory Compliance

In compliance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Poly Medicure has informed the stock exchanges about the record date and book closure details. The company secretary, Avinash Chandra, has signed the official intimation to the BSE Limited and the National Stock Exchange of India Limited.

Company Background

Poly Medicure Limited, with its registered office in New Delhi, is known for its contributions to the medical devices sector.

Investors and shareholders are advised to take note of the important dates related to the dividend announcement and the upcoming Annual General Meeting. The dividend payout, once approved by shareholders, will reward investors for their continued support of the company's growth and performance in the fiscal year 2024-25.

Poly Medicure Limited , a prominent player in the medical devices industry, has taken a significant step towards transparency by making available the audio recording of a recent analyst and investor conference call. The call, which took place on September 4, 2025, at 4:00 PM Indian time, focused on the company's proposed acquisition of the PendraCare Group.

Key Highlights

• Conference Call Details: The call was held on September 4, 2025, at 4:00 PM Indian time.
• Topic of Discussion: The proposed acquisition of PendraCare Group.
• Accessibility: The audio recording is now available on Poly Medicure's official website.
• Regulatory Compliance: This move aligns with the company's commitment to meeting regulatory requirements.

Acquisition Details

According to the LODR (Listing Obligations and Disclosure Requirements) data, Poly Medicure has entered into a Share Purchase Agreement (SPA) through its wholly-owned step-down subsidiary, RisoR Holdings B.V., based in Amsterdam, Netherlands. The agreement is with Wellinq Holdings B.V., also located in Amsterdam, Netherlands.

Key Points of the Acquisition

• Target Companies: The acquisition involves Pendracare Holdings B.V. and Wellinq Medical B.V., collectively referred to as the "PendraCare Group".
• Ownership Structure: Post-acquisition, Poly Medicure Limited, through RisoR Holding B.V., will own 90% of the economic rights in the PendraCare Group.
• Strategic Move: This acquisition is expected to strengthen Poly Medicure's position in the medical devices sector.

Implications for Investors

The release of the conference call audio recording demonstrates Poly Medicure's commitment to keeping its investors and analysts well-informed about significant corporate actions. This level of transparency is particularly crucial given the scale and potential impact of the PendraCare Group acquisition on the company's future operations and market position.

Regulatory Compliance

The company has emphasized that the audio recording's release is in compliance with Regulation 30 and 46(2)(oa) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This adherence to regulatory standards underscores Poly Medicure's dedication to maintaining good corporate governance practices.

Conclusion

As Poly Medicure Limited moves forward with its acquisition plans, the availability of the conference call recording provides stakeholders with valuable insights into the company's strategic direction. Investors and analysts are encouraged to access the recording on the company's website for a comprehensive understanding of the proposed PendraCare Group acquisition and its potential implications for Poly Medicure's future growth trajectory.